Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Application Type (Screening, Companion Diagnostics, and Other Diagnostics), By End User (Hospitals, Clinics, and Laboratories), By Technology Type (Whole Genome Sequencing, Whole Exome Sequencing, and Targeted Sequencing & Resequencing), By Workflow Type (NGS Pre-Sequencing, NGS Sequencing, and NGS Data Analysis), By Region, And By Segment Forecasts, 2025-2034

Report Id: 2249 Pages: 179 Last Updated: 06 May 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Global Clinical Oncology Next Generation Sequencing Market-

Clinical Oncology Next Generation Sequencing Market By Technology Type-

  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing & Re-sequencing 

Clinical Oncology Next Generation Sequencing Market

Clinical Oncology Next Generation Sequencing Market By End-User-

  • Hospitals
  • Clinics
  • Laboratories

Clinical Oncology Next Generation Sequencing Market By Application-

  • Screening
  • Companion Diagnostics
  • Other Diagnostics

Clinical Oncology Next Generation Sequencing Market By Workflow Type-

  • NGS Pre-Sequencing
  • NGS Sequencing
  • NGS Data Analysis

Clinical Oncology Next Generation Sequencing Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Clinical Oncology Next Generation Sequencing Market Snapshot

Chapter 4. Global Clinical Oncology Next Generation Sequencing Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Application Type Estimates & Trend Analysis

5.1. By Application Type, & Market Share, 2024 & 2034

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application Type:

5.2.1. Screening

5.2.2. Companion Diagnostics

5.2.3. Other Diagnostics

Chapter 6. Market Segmentation 2: By End User Estimates & Trend Analysis

6.1. By End User & Market Share, 2023 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End User:

6.2.1. Hospitals

6.2.2. Clinics

6.2.3. Laboratorie

Chapter 7. Market Segmentation 3: By Technology Type Estimates & Trend Analysis

7.1. By Technology Type & Market Share, 2023 & 2031

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Technology Type:

7.2.1. Whole Genome Sequencing

7.2.2. Whole Exome Sequencing

7.2.3. Targeted Sequencing & Resequencing

Chapter 8. Market Segmentation 4: By Workflow Type Estimates & Trend Analysis

8.1. By Workflow Type & Market Share, 2023 & 2031

8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Workflow Type:

8.2.2. NGS Pre-Sequencing

8.2.3. NGS Sequencing

8.2.4. NGS Data Analysis

Chapter 9. Clinical Oncology Next Generation Sequencing Market Segmentation 5: Regional Estimates & Trend Analysis

9.1. North America

9.1.1. North America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) estimates and forecasts By Application Type, 2021-2034

9.1.2. North America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) estimates and forecasts By End User, 2021-2034

9.1.3. North America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) estimates and forecasts By Technology Type, 2021-2034

9.1.4. North America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) estimates and forecasts By Workflow Type, 2021-2034

9.1.5. North America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) estimates and forecasts by country, 2021-2034

9.2. Europe

9.2.1. Europe Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Application Type, 2021-2034

9.2.2. Europe Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By End User, 2021-2034

9.2.3. Europe Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Technology Type, 2021-2034

9.2.4. Europe Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Workflow Type, 2021-2034

9.2.5. Europe Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) by country, 2021-2034

9.3. Asia Pacific

9.3.1. Asia Pacific Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Application Type, 2021-2034

9.3.2. Asia Pacific Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By End User, 2021-2034

9.3.3. Asia Pacific Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Technology Type, 2021-2034

9.3.4. Asia Pacific Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Workflow Type, 2021-2034

9.3.5. Asia Pacific Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) by country, 2021-2034

9.4. Latin America

9.4.1. Latin America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Application Type, 2021-2034

9.4.2. Latin America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By End User, 2021-2034

9.4.3. Latin America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Technology Type, 2021-2034

9.4.4. Latin America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Workflow Type, 2021-2034

9.4.5. Latin America Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) by country, 2021-2034

9.5. Middle East & Africa

9.5.1. Middle East & Africa Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Application Type, 2021-2034

9.5.2. Middle East & Africa Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By End User, 2021-2034

9.5.3. Middle East & Africa Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Technology Type, 2021-2034

9.5.4. Middle East & Africa Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) By Workflow Type, 2021-2034

9.5.5. Middle East & Africa Clinical Oncology Next Generation Sequencing Market revenue (US$ Million) by country, 2021-2034

Chapter 10. Competitive Landscape

10.1. Major Mergers and Acquisitions/Strategic Alliances

10.2. Company Profiles

10.2.1. llumina Inc.

10.2.2. Thermo Fisher Scientific

10.2.3. F. Hoffmann-La Roche Ltd.

10.2.4. Agilent Technologies

10.2.5. Myriad Genetics

10.2.6. Perkin Elmer

10.2.7. Caris Life Sciences

10.2.8. Partek, Inc.

10.2.9. Eurofins Scientific

10.2.10. Qiagen N.V. 

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
6338
Security Code field cannot be blank!

Frequently Asked Questions

Clinical Oncology Next Generation Sequencing Market Size is predicted to reach record a 16.0% CAGR during the forecast period for 2025-2034.

Oxford Nanopore Technologies Ltd., Paradigm Diagnostics, Beijing Genomics Institute (BGI), Takara Bio, Inc, Creative-Biolabs, and Others

Clinical Oncology Next Generation Sequencing Market Size is valued at USD 474.2 Mn in 2024 and is predicted to reach USD 2,069.7 Mn by the year 2034

Clinical Oncology Next Generation Sequencing Market is segmented on the basis of technology type, end-user, application, and workflow type.

North America region is leading the Clinical Oncology Next Generation Sequencing Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying